BARTALUCCI, NICCOLO'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.994
NA - Nord America 1.798
AS - Asia 361
AF - Africa 14
SA - Sud America 2
Totale 4.169
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.793
RU - Federazione Russa 634
PL - Polonia 622
IT - Italia 254
IE - Irlanda 175
SE - Svezia 126
CN - Cina 104
SG - Singapore 88
HK - Hong Kong 80
CH - Svizzera 58
IN - India 39
DE - Germania 36
GB - Regno Unito 26
FI - Finlandia 24
JO - Giordania 24
VN - Vietnam 14
CI - Costa d'Avorio 13
BE - Belgio 10
UA - Ucraina 8
KR - Corea 7
CA - Canada 5
ES - Italia 5
FR - Francia 5
NL - Olanda 4
AT - Austria 3
TR - Turchia 3
AE - Emirati Arabi Uniti 2
BR - Brasile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
MU - Mauritius 1
RO - Romania 1
Totale 4.169
Salva come PNG Salva come JPEG
Città #
Warsaw 622
Fairfield 285
Dublin 175
Chandler 162
Ashburn 161
Seattle 136
Woodbridge 136
Houston 112
Cambridge 104
Wilmington 94
Ann Arbor 88
Singapore 70
Altamura 59
Bern 58
Lawrence 58
Florence 57
Beijing 53
Hong Kong 46
Princeton 42
Mumbai 33
Buffalo 31
Boston 27
Bremen 23
Moscow 21
Shanghai 20
Medford 17
New York 17
Kent 16
San Diego 14
Abidjan 13
Dong Ket 12
Rome 12
Jacksonville 11
Brussels 10
Boardman 9
Falls Church 9
Los Angeles 9
Santa Clara 9
Milan 8
West Jordan 8
Seoul 7
Helsinki 6
Norwalk 6
Pian di Scò 6
Pune 6
Hillsboro 5
Phoenix 5
Rignano sull'Arno 5
Cagliari 4
Sesto Fiorentino 4
Siena 4
Toronto 4
Amsterdam 3
Andover 3
Basauri 3
Bologna 3
Cerignola 3
Dearborn 3
Fiesole 3
Fontebuona 3
Munich 3
Redwood City 3
San Jose 3
Vienna 3
Zhengzhou 3
Abu Dhabi 2
Arzachena 2
Farra di Soligo 2
Hefei 2
Izmir 2
Lappeenranta 2
Palermo 2
Paris 2
Pavia 2
Reston 2
Salerno 2
Seville 2
Turin 2
Vicopisano 2
Villa Minozzo 2
Azzano Decimo 1
Brescia 1
Brugherio 1
Camaiore 1
Castelliri 1
Catania 1
Clifton 1
Fiumicino 1
Forlì 1
Fuzhou 1
Grafing 1
Guangzhou 1
Heze 1
Inverigo 1
Kunming 1
Landshut 1
Livorno 1
Lugo di Vicenza 1
Monmouth Junction 1
Montalto 1
Totale 2.998
Salva come PNG Salva come JPEG
Nome #
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 266
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 246
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 240
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 211
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 166
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 161
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 129
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 121
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 120
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 120
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 116
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 111
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 108
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 103
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 102
Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing 97
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis 95
Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice 94
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 90
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 89
Novel insights into myelofibrosis pathophysiology and treatment 89
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 88
Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche 87
Rationale for combination therapies in myelofibrosis 83
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis 80
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 79
Preclinical models for drug selection in myeloproliferative neoplasms. 76
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 75
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. 71
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs 67
NANOR: A user-friendly R package to analyze and compare nanopore sequencing data 62
JAK PI3K/mTOR COMBINATION THERAPY 60
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 59
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 57
Peripheral nerve resident macrophages and schwann cells mediate cancer-induced pain A C 52
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 49
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 43
A blood drop through the pore: nanopore sequencing in hematology 42
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis 39
Polycythemia vera: the current status of preclinical models and therapeutic targets 36
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model 31
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. 24
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 24
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives 20
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 19
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells 17
Resolving complex structural variants via nanopore sequencing 17
Targeting the PI3K pathway in myeloproliferative neoplasms 9
Totale 4.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.659
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020713 0 0 0 76 102 102 85 104 86 73 69 16
2020/2021503 29 49 29 97 36 37 26 32 50 58 38 22
2021/2022299 8 10 40 6 9 18 5 26 24 15 54 84
2022/2023842 69 176 47 59 44 134 108 51 63 6 18 67
2023/2024404 17 33 54 19 43 53 6 81 12 30 36 20
2024/2025816 74 243 153 346 0 0 0 0 0 0 0 0
Totale 4.240